Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Beuers

Showing results (261-270 of 298) with videos related to

Pageof 30
Sort By:
Hepatology (Baltimore, Md.)|September 19, 2017
MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activationOihane Erice, Patricia Munoz-Garrido, Javier Vaquero, et al.
Hepatology (Baltimore, Md.)|June 19, 2013
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitisKirsten Boonstra, Rinse K Weersma, Karel J van Erpecum, et al.
Journal of Hepatology|June 6, 2015
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver diseasePatricia Munoz-Garrido, José J G Marin, María J Perugorria, et al.
Lancet (London, England)|January 15, 2017
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trialMeike H van der Ree, J Marleen de Vree, Femke Stelma, et al.
Journal of Hepatology|September 20, 2012
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remissionNicole M F van Gerven, Bart J Verwer, Birgit I Witte, et al.
JHEP Reports : Innovation in Hepatology|July 8, 2024
Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapyAnna E C Stoelinga, Maaike Biewenga, Joost P H Drenth, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 5, 2013
Cytotoxic T lymphocyte antigen-4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitisNicole M F van Gerven, Ynto S de Boer, Antonie Zwiers, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 11, 2022
Disease burden and management of Crigler-Najjar syndrome: Report of a world registrySem J Aronson, Norman Junge, Mediha Trabelsi, et al.
The Lancet. Gastroenterology & Hepatology|October 15, 2019
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trialElisa Pose, Laura Napoleone, Ahmed Amin, et al.
Nature Medicine|October 10, 2022
Microbiome-derived ethanol in nonalcoholic fatty liver diseaseAbraham S Meijnikman, Mark Davids, Hilde Herrema, et al.
Pageof 30

Showing results (261-270 of 298) with videos related to

Sort By:
Pageof 30
Hepatology (Baltimore, Md.)|September 19, 2017
MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activationOihane Erice, Patricia Munoz-Garrido, Javier Vaquero, et al.
Hepatology (Baltimore, Md.)|June 19, 2013
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitisKirsten Boonstra, Rinse K Weersma, Karel J van Erpecum, et al.
Journal of Hepatology|June 6, 2015
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver diseasePatricia Munoz-Garrido, José J G Marin, María J Perugorria, et al.
Lancet (London, England)|January 15, 2017
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trialMeike H van der Ree, J Marleen de Vree, Femke Stelma, et al.
Journal of Hepatology|September 20, 2012
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remissionNicole M F van Gerven, Bart J Verwer, Birgit I Witte, et al.
JHEP Reports : Innovation in Hepatology|July 8, 2024
Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapyAnna E C Stoelinga, Maaike Biewenga, Joost P H Drenth, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 5, 2013
Cytotoxic T lymphocyte antigen-4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitisNicole M F van Gerven, Ynto S de Boer, Antonie Zwiers, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 11, 2022
Disease burden and management of Crigler-Najjar syndrome: Report of a world registrySem J Aronson, Norman Junge, Mediha Trabelsi, et al.
The Lancet. Gastroenterology & Hepatology|October 15, 2019
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trialElisa Pose, Laura Napoleone, Ahmed Amin, et al.
Nature Medicine|October 10, 2022
Microbiome-derived ethanol in nonalcoholic fatty liver diseaseAbraham S Meijnikman, Mark Davids, Hilde Herrema, et al.
Pageof 30